Medically reviewed by David Ozeri, MD Complement 3 glomerulopathy (C3G) is a rare kidney disorder—in many cases, the exact ...

Medically reviewed by Femi Aremu, PharmD Complement 3 glomerulopathy (C3G) is a rare type of kidney disease. There are two types: C3 glomerulonephritis (C3GN) and dense deposit disease (DDD).C3GN is ...

European Commission approves Sobi’s Aspaveli for the treatment of C3G and primary IC-MPGN: Stockholm Monday, January 19, 2026, 10:00 Hrs [IST] Sobi, a global biopharma company u ...

Approximately 8,000 people in Europe are living with C3G or primary IC-MPGN Aspaveli (pegcetacoplan) is the first treatment of primary IC-MPGN and the ...

Approximately 8,000 people in Europe are living with C3G or primary IC-MPGN Aspaveli (pegcetacoplan) is the first treatment of primary IC-MPGN and the first treatment for C3G and primary IC-MPGN ...

Apellis Pharmaceuticals (NASDAQ:APLS) used its presentation at the 44th Annual JPMorgan Healthcare Conference to outline its ...

Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% ...

C3.ai’s (AI) stock fell 14% after preliminary Q1 2026 results and another 5% post-full earnings. The company struggles to profit from the AI boom, unlike competitors. The Wall Street adage shifts for ...

NEW data from the phase 3 VAILANT trial presented at ERA 2025 Congress, highlighted the potential of pegcetacoplan to modify disease progression in patients with C3 glomerulopathy (C3G) and primary ...

Background: Pulmonary arterial hypertension (PAH) is a severe condition characterized by pulmonary vascular remodelling leading to right ventricle failure. Emerging evidence highlights inflammation as ...